Gilead's remdesivir slows disease progression in monkeys with COVID-19

[June 09, 2020]  (Reuters) - Gilead Sciences Inc's antiviral drug, remdesivir, prevented lung disease in macaques infected with the new coronavirus, according to a study published in medical journal Nature on Tuesday.

Remdesivir has been cleared for emergency use in severely-ill patients in the United States, India and South Korea. Some European nations are also using it under compassionate programs.

Trials of the drug in humans are ongoing, and early data has shown the drug helped patients recover more quickly from the illness caused by the new coronavirus.

In the study, 12 monkeys were deliberately infected with the coronavirus, and half of them were given early treatment with remdesivir.

Macaques that received remdesivir did not show signs of respiratory disease and had reduced damage to the lungs, according to the study authors. https://go.nature.com/2Yj9xq2

(Reporting by Manas Mishra in Bengaluru; Editing by Saumyadeb Chakrabarty)

[© 2020 Thomson Reuters. All rights reserved.]

Copyright 2020 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.